Most Recent
HWL Ebsworth has won final orders barring unknown Russian-linked hackers from disseminating confidential information stolen during an April 2023 cyberattack.
The former director of collapsed investment advisor Linchpin Capital hit hardest by a judgment disqualifying him and three other directors and levying a combined $390,000 in penalties has filed an appeal.
PricewaterhouseCoopers has been slammed for refusing to release a report by law firm Linklaters into alleged wrongdoing by international partners, with a senator saying the firm was “hiding behind” privilege after it made thousands of such claims during an ATO investigation.
International Capital Markets may soon face a third class action, a court has heard, as the first two class actions to be filed against the Sydney-based online broker over risky contracts for difference mull consolidation.
Digital currency exchange Block Earner needed a licence to offer its crypto-backed Earner product, a court has found in one of the first decisions on the application of financial services law to crypto investments.
A judge has held that there could be favourable costs consequences for Carnival if its rejected $15 million settlement offer in the Ruby Princess class action turns out to be more generous than the ultimate damages award, departing from a previous ruling that so-called Calderbank offers do not operate in group proceedings.
Two marine freight companies have lost a fight with a local council which refused to allow it to unload 3,000 head of cattle at Apollo Bay in Victoria, with a judge finding they were “the architects of their own misfortune” for striking a deal with a beef company before securing permission to berth at the port.
The High Court has refused special leave in a failed class action against Volkswagen over allegedly defective Takata airbags.
A former Greenwoods & Herbert Smith Freehills partner who alleges he was sacked for complaining about Lendlease's "aggressive taxation position" has lost a bid to argue before the High Court that his claims are covered by new whistleblower protections.
South Korean biosimilars company Samsung Bioepis has sued Johnson & Johnson's Janssen Biotech to invalidate two patents for Crohn's disease drug Stelara, after reaching a licencing agreement over the medicine in the US.